SuppreMol to Use Protagen Biomarker Panel | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biopharma company SuppreMol will use Protagen's biomarker portfolio to identify markers that may be predictive of which patients may be the best candidates for SuppreMol's lead therapy systemic lupus erythematosus (SLE), the companies said today.

Under the agreement, SuppreMol will use Protagen's UNIarray technology platform in phase IIa clinical trials for a personalized therapy for SLE called SM101.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.